摘要
目的观察低分子肝素治疗不稳定型心绞痛患者的临床疗效与安全性。方法将收入院的100例不稳定型心绞痛患者按1∶1比例随机分为观察组和对照组。对照组采用休息、吸氧、止痛、镇静、扩冠、降压和抗血小板聚集药物等基础治疗4周,并在前14 d静点丹参酮注射液50 mg加入5%葡萄糖注射液200mL中,口服欣康缓释片40 mg,1次/d。观察组除上述治疗外,在前7 d加用国产低分子肝素4 100 IU,2次/d皮下注射。结果对照组显效18例,有效2例,无效9例,有效率82%。无效病例中4例发展为急性心肌梗死,死亡1例。治疗组显效5例,有效20例,无效5例,总有效率为90%。两组比较差异显著(P<0.05)。结论低分子肝素用于治疗不稳定型心绞痛患者,能有效改变其血液凝固性和预防急性心肌梗死的发生。同时,该药对患者PT值和血小板计数无显著影响,临床应用未见出血现象,具有较高的安全性。
Objective To observe the clinical effect and safety of unstable angina with low molecular heparin. Methods 100 cases of tmstable angina were taken as observe group and other 100 patients were taken as control group. The control group was treated with routinely for 4 weeks, The observe group was treated with LMH on the bases of routine therapy. Results 18 cases in control group were excellent, 2 cases effective and 9 cases non - effective with effective rate of 82%. 5 eases in observe group were excellent, 20 cases effective and 5 cases non - effective with effective rate of 90%. There was significant difference between two groups. Conclusion The LMH might treat the unstable angina effectively to change the coagulating status and prevent the AMI with safety on PT and Pit.
出处
《黑龙江医学》
2006年第5期375-376,共2页
Heilongjiang Medical Journal
